| Dr Julie Ann Belanger, OD | |
|
518 Greenville Blvd Se Ste F, Greenville, NC 27858-6758 | |
| (252) 756-1078 | |
| (252) 756-8814 |
| Full Name | Dr Julie Ann Belanger |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 19 Years |
| Location | 518 Greenville Blvd Se Ste F, Greenville, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427036953 | NPI | - | NPPES |
| NC1929A314 | Other | NC | MEDICARE PTAN |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wilcox Optometry Pllc | 9234533092 | 5 |
News Archive
A novel non-invasive device which separates healthy and damaged heart muscle and restores ventricle function improves 3 year outcomes in patients with ischemic heart failure, according to research presented at the ESC Congress 2012.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
The last time heroin landed Marissa Angerer in a Midland, Texas, emergency room — naked and unconscious — was May 2016. But that wasn't her first drug-related interaction with the health system.
The LSL60101 compound, a specific ligand of the I2-IR receptors in the brain, could shed light on the development of future strategies against Alzheimer's disease.
A new device that combines low-intensity laser light and therapeutic ultrasound considerably reduces the pain experienced by patients with fibromyalgia.
› Verified 9 days ago
| Provider Name | Insight Family And Pediatric Eye Care |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588945778 PECOS PAC ID: 5193996890 Enrollment ID: O20110928000567 |
News Archive
A novel non-invasive device which separates healthy and damaged heart muscle and restores ventricle function improves 3 year outcomes in patients with ischemic heart failure, according to research presented at the ESC Congress 2012.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
The last time heroin landed Marissa Angerer in a Midland, Texas, emergency room — naked and unconscious — was May 2016. But that wasn't her first drug-related interaction with the health system.
The LSL60101 compound, a specific ligand of the I2-IR receptors in the brain, could shed light on the development of future strategies against Alzheimer's disease.
A new device that combines low-intensity laser light and therapeutic ultrasound considerably reduces the pain experienced by patients with fibromyalgia.
› Verified 9 days ago
| Provider Name | Wilcox Optometry Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1407529696 PECOS PAC ID: 9234533092 Enrollment ID: O20210802002357 |
News Archive
A novel non-invasive device which separates healthy and damaged heart muscle and restores ventricle function improves 3 year outcomes in patients with ischemic heart failure, according to research presented at the ESC Congress 2012.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
The last time heroin landed Marissa Angerer in a Midland, Texas, emergency room — naked and unconscious — was May 2016. But that wasn't her first drug-related interaction with the health system.
The LSL60101 compound, a specific ligand of the I2-IR receptors in the brain, could shed light on the development of future strategies against Alzheimer's disease.
A new device that combines low-intensity laser light and therapeutic ultrasound considerably reduces the pain experienced by patients with fibromyalgia.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Julie Ann Belanger, OD 5430 Echo Ridge Rd, Raleigh, NC 27612-6949 Ph: (919) 741-7525 | Dr Julie Ann Belanger, OD 518 Greenville Blvd Se Ste F, Greenville, NC 27858-6758 Ph: (252) 756-1078 |
News Archive
A novel non-invasive device which separates healthy and damaged heart muscle and restores ventricle function improves 3 year outcomes in patients with ischemic heart failure, according to research presented at the ESC Congress 2012.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
The last time heroin landed Marissa Angerer in a Midland, Texas, emergency room — naked and unconscious — was May 2016. But that wasn't her first drug-related interaction with the health system.
The LSL60101 compound, a specific ligand of the I2-IR receptors in the brain, could shed light on the development of future strategies against Alzheimer's disease.
A new device that combines low-intensity laser light and therapeutic ultrasound considerably reduces the pain experienced by patients with fibromyalgia.
› Verified 9 days ago
Clayton Davis, Od, Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 210 Sw Greenville Blvd, Greenville, NC 27834 Phone: 252-355-2441 | |
Dr. Eileen M Weitzel, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 116 Regency Blvd, Greenville, NC 27834 Phone: 252-754-2020 Fax: 252-493-0100 | |
Fishel Eyecare Od Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2797 Charles Blvd, Greenville, NC 27858 Phone: 502-244-2441 Fax: 502-996-8282 | |
Myeyedr Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1840 W Arlington Blvd, Greenville, NC 27834 Phone: 252-752-2171 Fax: 252-758-5104 | |
Joelle Fisher, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1804 W Arlington Blvd, Greenville, NC 27834 Phone: 252-752-4380 | |
Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 2573 Stantonsburg Rd, Greenville, NC 27834 Phone: 252-758-2100 Fax: 252-758-2103 | |
Dr. Scott J Mcintosh, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1804 W Arlington Blvd, Greenville, NC 27834 Phone: 252-752-4380 Fax: 252-757-0419 |